TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$36.36-0.71%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · TEVA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks TEVA against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue growing key innovative brands AUSTEDO, AJOVY, and UZEDY to transform portfolio mix and financial profile.
Stated as a priority in 2 of last 2 quarters. Key innovative brands grew 41% YoY in local currency in Q1 2026 and 43% YoY in Q2 2026, generating over $1 billion in Q2 revenues. Management has raised the 2026 revenue outlook for these brands, indicating delivery on growth focus.
“Key innovative brands collectively grew 43% YoY in LC in Q2 2026 to over $1 billion in revenues.”
“AUSTEDO, AJOVY, and UZEDY revenues collectively grew by 41% YoY in LC to $838 million in Q1 2026.”
Progress late-stage pipeline assets including ecopipam NDA submission, olanzapine LAI launch preparation, and Phase 3 studies for duvakitug.
Stated as a priority in 2 of last 2 quarters. Management reported NDA submission for ecopipam in June 2026, EMA acceptance of olanzapine LAI MAA, and on-track Phase 3 enrollment for duvakitug. These milestones demonstrate active advancement of the late-stage pipeline.
“NDA for ecopipam submitted to FDA in June 2026; EMA accepted olanzapine LAI MAA; Phase 3 enrollment on track for duvakitug.”
Expand biosimilars portfolio including launches in Europe and collaborations to develop new biosimilars.
Stated as a priority in 2 of last 2 quarters. Management reported European launch of AHZANTIVE, licensing agreement for biosimilar to Ocrevus, and biosimilars on track for $800 million revenues by 2027. Biosimilars portfolio growth and regulatory approvals indicate progress sustaining this priority.
“Launched AHZANTIVE in Europe; licensing agreement with Polpharma for biosimilar to Ocrevus; biosimilars on track for $800 million revenues by 2027.”
Continue Teva Transformation programs targeting approximately $700 million net savings by 2027, with two-thirds expected in 2026.
Stated as a priority in 2 of last 2 quarters. Management expects ~$700 million net savings through 2027 from Teva Transformation programs, with two-thirds targeted in 2026. While specific savings numbers for 2026 are not disclosed, the company reports being on track, indicating progress but limited detailed delivery data.
“Expect to realize two-thirds of targeted savings in 2026 through Teva Transformation programs.”
Focus on disciplined capital allocation with free cash flow guidance of $2.0 - $2.4 billion for 2026.
Stated as a priority in 2 of last 2 quarters. Management maintained free cash flow guidance of $2.0 - $2.4 billion for 2026. Actual free cash flow was $622 million in Q2 2026 and $188 million in Q1 2026, indicating ongoing generation consistent with guidance and disciplined capital allocation.
Over the trailing year it converted 2.68x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 55% of the time over the next year (vs 45% for the rest of the cohort, n=2490).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, the US dollar, Fed net liquidity, long-term interest rates (low R² over the window).
5 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
“NDA for olanzapine LAI accepted by FDA in February 2026; Phase 3 enrollment on target for duvakitug in UC and CD.”
“Biosimilars portfolio showed strong growth; PONLIMSI approved by FDA; applications accepted for biosimilar to Xolair by FDA and EMA.”
“Programs expected to generate ~$700 million net savings through 2027; on track to deliver two-thirds of savings in 2026.”
“Free cash flow of $2.0 - $2.4 billion expected for 2026.”
“Free cash flow guidance of $2.0 - $2.4 billion maintained for 2026.”